Back to Search Start Over

Use of mexiletine in therapy-refractory recurrent ventricular tachycardia storm.

Authors :
Szonyi MD
Pap R
Vamos M
Source :
Herzschrittmachertherapie & Elektrophysiologie [Herzschrittmacherther Elektrophysiol] 2023 Dec; Vol. 34 (4), pp. 326-329. Date of Electronic Publication: 2023 Nov 02.
Publication Year :
2023

Abstract

Electrical storm due to recurrent ventricular tachycardias (VTs) is a life-threatening arrhythmic emergency. The authors present a case report of a 69-year-old male patient with VT storm of non-ischemic etiology. Despite optimal medical treatment escalated by amiodarone antiarrhythmic drug therapy, the patient experienced multiple implantable cardioverter defibrillator (ICD) shocks. An electrophysiological study revealed an epicardial substrate; however, considering the patient's extreme obesity and active anticoagulant effect, catheter ablation was deemed to be unfeasible. Subsequently, mexiletine was added to the patient's drug regimen, resulting in successful control of arrhythmias during the following 6 months. Although the most recent European guidelines for the management of patients with ventricular arrhythmias mention mexiletine only for the treatment of LQT3 patients, its use for treatment-refractory VT storm seems to also be an important indication area.<br /> (© 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.)

Details

Language :
English
ISSN :
1435-1544
Volume :
34
Issue :
4
Database :
MEDLINE
Journal :
Herzschrittmachertherapie & Elektrophysiologie
Publication Type :
Academic Journal
Accession number :
37917362
Full Text :
https://doi.org/10.1007/s00399-023-00976-x